Second generation β-elemene nitric oxide derivatives with reasonable linkers: potential hybrids against malignant brain glioma
| Autor: | Renren Bai, Junlong Zhu, Ziqiang Bai, Qing Mao, Yingqian Zhang, Zi Hui, Xinyu Luo, Xiang-Yang Ye, Tian Xie |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 37, Iss 1, Pp 379-385 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1475-6366 1475-6374 14756366 |
| DOI: | 10.1080/14756366.2021.2016734 |
| Popis: | Elemene is a second-line broad-spectrum anti-tumour drug that has been used in China for more than two decades. However, its main anti-tumour ingredient, β-elemene, has disadvantages, including excessive lipophilicity and relatively weak anti-tumour efficacy. To improve the anti-tumour activity of β-elemene, based on its minor molecular weight character, we introduced furoxan nitric oxide (NO) donors into the β-elemene structure and designed six series of new generation β-elemene NO donor hybrids. The synthesised compounds could effectively release NO in vitro, displayed significant anti-proliferative effects on U87MG, NCI-H520, and SW620 cell lines. In the orthotopic glioma model, compound Id significantly and continuously suppressed the growth of gliomas in nude mice, and the brain glioma of the treatment group was markedly inhibited (>90%). In short, the structural fusion design of NO donor and β-elemene is a feasible strategy to improve the in vivo anti-tumour activity of β-elemene. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|